Immunovant IMVT
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Immunovant (IMVT) Core Market Data and Business Metrics
Latest Closing Price
$16.42Price-Earnings Ratio
-7.40Total Outstanding Shares
169.86 Million SharesDividend
No dividendSIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
320 West 37th Street, New York, NY, 10018
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 1,090,795 Shares | 14.48 | 3/14/2025 | 15,799,702 Shares |
| 990,020 Shares | 15.55 | 2/28/2025 | 15,390,952 Shares |
| 1,658,194 Shares | 8.92 | 2/14/2025 | 14,788,106 Shares |
| 1,319,745 Shares | 9.96 | 1/31/2025 | 13,149,997 Shares |
| 960,266 Shares | 13.36 | 1/15/2025 | 12,832,296 Shares |
| 1,098,414 Shares | 11.16 | 12/31/2024 | 12,260,769 Shares |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities | $-659,000 |
| Net Cash Flow From Operating Activities | $-271.64 Million |
| Net Cash Flow, Continuing | $200.50 Million |
| Exchange Gains/Losses | $2.51 Million |
| Net Cash Flow From Investing Activities, Continuing | $-659,000 |
| Net Cash Flow From Financing Activities, Continuing | $472.81 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Income Tax Expense/Benefit | $279,000 |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Income/Loss From Continuing Operations Before Tax | $-322.73 Million |
| Basic Average Shares | $293.36 Million |
| Diluted Average Shares | $293.36 Million |
| Diluted Earnings Per Share | $-2.22 |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss Attributable To Parent | $-321.61 Million |
| Other Comprehensive Income/Loss | $-194.87 Million |
| Comprehensive Income/Loss | $-321.61 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Accounts Payable | $20.73 Million |
| Noncurrent Assets | $8.34 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
| Other Current Assets | $474.82 Million |
| Current Liabilities | $66.65 Million |
| Current Assets | $507.37 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||